You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

Drugs in MeSH Category Muscarinic Agonists


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 040721-001 Nov 1, 2006 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Impax Labs BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 040721-003 Nov 1, 2006 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Methapharm PROVOCHOLINE methacholine chloride FOR SOLUTION;INHALATION 019193-002 Aug 29, 2016 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Teva Branded Pharm URECHOLINE bethanechol chloride TABLET;ORAL 006536-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Watson Labs BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 085228-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Able BETHANECHOL CHLORIDE bethanechol chloride TABLET;ORAL 040509-001 Jul 27, 2004 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Muscarinic Agonists Market Analysis and Financial Projection

The muscarinic agonists market is experiencing significant growth driven by advances in neuropharmacology and increasing demand for treatments targeting neurological and psychiatric disorders. Here's an analysis of the market dynamics and patent landscape:


Market Growth and Projections

  • The global muscarinic acetylcholine receptor market is projected to reach $2.37 billion by 2029, growing at a 5.8% CAGR [2][7]. This growth is fueled by:

    • Rising neurological disorder prevalence (e.g., Alzheimer's disease, schizophrenia).
    • Innovations in selective M1/M4 receptor agonists with improved tolerability [6][10].
    • Expansion into gastrointestinal and respiratory therapies [2][7].
  • M4 receptor-specific markets are growing faster, with forecasts predicting $1.56 billion by 2033 (8.7% CAGR) due to their role in cognitive and motor regulation [12].


Therapeutic Applications and Key Drugs

Neurological Disorders

  • Schizophrenia:

    • Xanomeline/trospium chloride (approved in 2024) reduces psychosis and improves cognition by targeting M1/M4 receptors [3][13].
    • ML-007/PAC (MapLight Therapeutics) entered Phase 2 trials in 2025, emphasizing reduced side effects [10].
  • Alzheimer’s Disease:

    • M1 agonists like AF267B and AF102B show neuroprotective effects, reducing amyloid plaques and oxidative stress [3][13].

Other Applications

  • Dry mouth (Sjögren's syndrome): Cevimeline (FDA-approved M3 agonist) [3].
  • Glaucoma: Pilocarpine remains a cornerstone therapy [3].

Patent Landscape

Key Innovations

Patent Focus Examples Significance
M1/M4 selective agonists CA2993484C (azaspiro compounds), WO2017021730A1 (piperidin derivatives) [1][15] Improved receptor specificity reduces side effects like nausea [1][15].
Formulation advances US10925832B2 (xanomeline extended-release combinations) [13] Enhances patient compliance through once-daily dosing [13].
Pain management US20050130961A1 (M1 agonists for neuropathic pain) [14] Addresses unmet needs in chronic pain treatment [14].

Trends

  • Rising filings for subtype-selective agonists: Over 60% of recent patents focus on M1/M4 receptors [1][15].
  • Combination therapies: Patents like US10925832B2 highlight formulations pairing muscarinic agonists with anticholinergics to mitigate side effects [13].

Competitive Landscape

  • Major players: MapLight Therapeutics, Heptares (partnered with Allergan), and Allergan lead clinical development [6][10].
  • Strategic partnerships: Licensing deals (e.g., Heptares-Allergan’s $125M agreement) accelerate R&D for CNS disorders [6].

Challenges and Opportunities

  • Hurdles:

    • Balancing receptor selectivity to avoid off-target effects (e.g., M3-linked cardiovascular issues) [3].
    • High development costs for CNS drugs due to stringent regulatory requirements [10].
  • Opportunities:

    • Expanding indications: M4 agonists show promise in treating opioid addiction and Parkinson’s disease [8][12].
    • Personalized medicine: Genetic profiling to identify patients responsive to M1/M4 therapies [8].

MeSH Classification and Research Trends

  • MeSH ID: D018721 classifies muscarinic agonists under N07 ATC code, facilitating standardized research [3][11].
  • PubMed-indexed studies increased by 22% since 2020, focusing on receptor structure-function relationships [5][9].

"ML-007/PAC has demonstrated a favorable safety profile with once-daily dosing, representing a breakthrough in muscarinic agonist development." — MapLight Therapeutics, 2024 [10]

This sector’s evolution hinges on overcoming selectivity challenges and leveraging subtype-specific mechanisms. With over 200 GPCRs still underexplored, muscarinic agonists remain a frontier for neurodegenerative and psychiatric therapies [5][8].

References

  1. https://patents.google.com/patent/CA2993484C/en
  2. https://www.thebusinessresearchcompany.com/report/muscarinic-acetylcholine-receptor-global-market-report
  3. https://en.wikipedia.org/wiki/Muscarinic_agonist
  4. https://patents.google.com/patent/WO1998046231A1/en
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC8779880/
  6. https://www.science.org/content/blog-post/muscarinic-agonists-come-back-around
  7. http://www.einpresswire.com/article/734844229/muscarinic-acetylcholine-receptor-market-analysis-with-opportunity-segments-for-2024-2033
  8. https://pubmed.ncbi.nlm.nih.gov/35758639/
  9. https://www.nlm.nih.gov/databases/download/mesh.html
  10. https://www.prnewswire.com/news-releases/maplight-therapeutics-announces-results-from-phase-1-trial-of-novel-m1m4-muscarinic-agonist-in-development-for-treatment-of-schizophrenia-and-alzheimers-disease-psychosis-302317925.html
  11. https://en.wikipedia.org/wiki/Medical_Subject_Headings
  12. https://www.verifiedmarketreports.com/product/muscarinic-acetylcholine-receptor-m4-market/
  13. https://patents.google.com/patent/US10925832B2/en
  14. https://patents.google.com/patent/US20050130961
  15. https://patents.google.com/patent/WO2017021730A1/en)
  16. https://www.repository.cam.ac.uk/items/918ff7ca-2595-4661-8a9c-88e1dac0b5e5

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.